HepaRegeniX’s darizmetinib clears milestone in major liver resection patients, with favorable safety profile and Phase 2a advance lined up.
Link as first comment.
@longevitytech.bsky.social
Explore
@longevitytech.bsky.social
@longevitytech.bsky.socialHepaRegeniX’s darizmetinib clears milestone in major liver resection patients, with favorable safety profile and Phase 2a advance lined up.
Link as first comment.